Astrazeneca PLC AZN

What this company does

AstraZeneca researches, develops, manufactures and commercialises prescription medicines across primary care, specialty care and rare diseases. It keeps an active presence in more than 80 countries and sells its products in more than 125 countries. In most markets, medicines reach buyers through wholly-owned local marketing companies, distributors and local representative offices. Total Revenue in the US came to $25,450 million in 2025. The group runs three therapy area-focused R&D organisations: Oncology, BioPharmaceuticals and Rare Disease. Six strategic R&D centres are maintained, including one in Beijing. R&D employees numbered 16,100 across its global sites. Manufacturing sites employ 16,900 people.

Written from the business description in ASTRAZENECA PLC's annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.